- Home
- MDWD vs RGC Comparison
MDWD vs RGC Comparison
Compare MDWD & RGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDWD
- RGC
- Stock Information
- Founded
- MDWD 2000
- RGC 2014
- Country
- MDWD Israel
- RGC Hong Kong
- Employees
- MDWD N/A
- RGC N/A
- Industry
- MDWD Medicinal Chemicals and Botanical Products
- RGC Medicinal Chemicals and Botanical Products
- Sector
- MDWD Health Care
- RGC Health Care
- Exchange
- MDWD Nasdaq
- RGC Nasdaq
- Market Cap
- MDWD 208.2M
- RGC 38.6B
- IPO Year
- MDWD 2014
- RGC 2021
- Fundamental
- Price
- MDWD $20.72
- RGC $14.66
- Analyst Decision
- MDWD Strong Buy
- RGC
- Analyst Count
- MDWD 2
- RGC 0
- Target Price
- MDWD $35.00
- RGC N/A
- AVG Volume (30 Days)
- MDWD 50.6K
- RGC 2.8M
- Earning Date
- MDWD 08-13-2025
- RGC 06-30-2025
- Dividend Yield
- MDWD N/A
- RGC N/A
- EPS Growth
- MDWD N/A
- RGC N/A
- EPS
- MDWD N/A
- RGC N/A
- Revenue
- MDWD $19,213,000.00
- RGC N/A
- Revenue This Year
- MDWD $20.80
- RGC N/A
- Revenue Next Year
- MDWD $26.92
- RGC N/A
- P/E Ratio
- MDWD N/A
- RGC N/A
- Revenue Growth
- MDWD N/A
- RGC N/A
- 52 Week Low
- MDWD $14.14
- RGC $0.08
- 52 Week High
- MDWD $22.51
- RGC $83.60
- Technical
- Relative Strength Index (RSI)
- MDWD 64.88
- RGC 45.32
- Support Level
- MDWD $19.07
- RGC $9.39
- Resistance Level
- MDWD $19.55
- RGC $30.00
- Average True Range (ATR)
- MDWD 0.65
- RGC 6.44
- MACD
- MDWD 0.12
- RGC -1.70
- Stochastic Oscillator
- MDWD 94.01
- RGC 20.68
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.